Get the Stockscreener App
1.07
0.94%
0.01
Acurx Pharmaceuticals Inc stock is traded at $1.07, with a volume of 61,178.
It is up +0.94% in the last 24 hours and down -20.15% over the past month.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
See More
Previous Close:
$1.06
Open:
$1.08
24h Volume:
61,178
Relative Volume:
0.96
Market Cap:
$5.85M
Revenue:
Net Income/Loss:
$-7.50M
P/E Ratio:
-0.243
EPS:
-4.4035
Net Cash Flow:
$-6.14M
1W Performance:
-6.96%
1M Performance:
-20.15%
6M Performance:
-48.06%
1Y Performance:
-83.02%
1-Day Range:
$1.05
$1.0801
1-Week Range:
$1.05
$1.14
52-Week Range:
$1.05
$7.5392
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.07 | 5.85M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
ACXP S-1 & SEC Filings - Yahoo! Finance Canada
ACXP S-1 & SEC Filings - Yahoo! Finance Canada
ACXP S-1 & SEC Filings - Yahoo! Finance Canada
ACXP S-3/A & SEC Filings - Yahoo! Finance Canada
C. diff is associated with about 30,000 U.S. deaths a year. A trial for repeat infections has enrolled its first patient. - Stock Titan
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - easternprogress.com
Acurx Pharmaceuticals (NASDAQ: ACXP) May Generate Up to $2.8M Through Lincoln Park Capital Share Sales - Kalkine Media
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call - Benzinga
Acurx Pharmaceuticals files prospectus for $1.5 million SEC offering - scanx.trade
1.5M-share resale puts dilution on table at Acurx (ACXP). How much cash can it still tap? - Stock Titan
Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Acurx (ACXP) Quarterly Scorecard: The Available Earnings Metric Delivers a Beat on the Day; Shares Fall 4.76% in Latest TradingHealthcare Earnings Report - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - theglobeandmail.com
Acurx (ACXP) Price-Move Recap: Ends Down by 12.73% at $1.44 in the Latest Reading; Key Levels - vinanet.vn
Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com Nigeria
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView
Acurx Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 3ZO0 | US00510M2035 - marketscreener.com
Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com
Acurx Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | ACXP | US00510M2035 - marketscreener.com
Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade
Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang
Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey
Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - Yahoo Finance
ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView
Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) Debt 2025 - stocktitan.net
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics - Yahoo Finance
Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan
Acurx Pharmaceuticals, Inc. and Leiden University Medical Center Announce Scientific Partnership to Advance Development of Dna Polymerase IIIC Inhibitor Antibiotics - marketscreener.com
ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ACXP Q1 2026 Earnings: Narrower Net Loss Beats Expectations, Shares Rise 4.76%EPS Consistency Score - vinanet.vn
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program - TradingView
FDA Provides Further Regulatory Guidance to A - Moomoo
Acurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock Titan
Acurx Pharmaceuticals FDA open to single Phase 3 trial for ibezapolstat NDA - scanx.trade
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Continued R&D ExecutionEarnings Stability Report - vinanet.vn
ACXP Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline at a Pre-Revenue Stage - vinanet.vn
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
44.16%
6.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):